This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks to Watch Under $5

2. Immunomedics (IMMU - Get Report) focuses on the development of monoclonal antibody-based products for treating cancer, autoimmune and other serious diseases. The company has developed several advanced technologies enabling it to create humanized antibodies, which can be used either singly in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents.

Seventy-eight percent of the nine analysts covering the stock recommend a buy on it. The stock's average 12-month price target is $5.13, which is 53.4% higher than the current price, according to a Bloomberg consensus.

For 2012 first quarter, the company recorded net loss of $5.1 million, or 7 cents per share, as compared to net loss of $6.5 million, or 9 cents per share in the year-earlier period. Overall revenue for the quarter grew to $1.1 million from $1.5 million in the same quarter in previous year. Cash and cash equivalents at the end of the quarter were $20.7 million.

In the second half of December, the company and UCB S.A. announced restructuring of the epratuzumab license agreement, providing UCB the flexibility to choose a partner to sublicense its rights for certain territories. In addition, UCB returned its buy-in right for the cancer indication to Immunomedics. Same month, Immunomedics was granted a U.S. patent for increasing longevity and protein yield from a cell culture. Also, the company presented two preclinical studies with an objective to produce potent therapeutics for diverse epithelial carcinomas, including breast cancer.

For Clivatuzumab, the company completed enrollment for the phase Ib/II in patients with advanced pancreatic cancer and has begun preparations to launch a phase III pivotal trial of this agent for 2012.

4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ZQK $2.25 -0.44%
CRIS $2.58 1.18%
IMMU $3.71 -3.13%
NM $4.21 -2.30%
SIRI $3.86 0.78%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs